In addition, Li et al. found that deletion of ApoC3 from LDLR−/− mice has no impact on lipid metabolism and atherogenesis, indicating that targeting ApoC3 to treat hyperlipidemia and CVD needs to be further validated. The gene discussed is LDLR; the disease is hyperlipidemia.